| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/22/2004 | WO2004006865A2 Compounds, compositions, and methods |
| 01/22/2004 | WO2004006850A2 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS |
| 01/22/2004 | WO2004006847A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 01/22/2004 | WO2004006846A2 Receptor-type kinase modulators and methods of use |
| 01/22/2004 | WO2004006842A2 Combinations of drugs for the treatment of neoplasms |
| 01/22/2004 | WO2004006835A2 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 01/22/2004 | WO2004006662A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARα GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 01/22/2004 | WO2003097665A3 Mid 241 receptor, a novel g-protein coupled receptor |
| 01/22/2004 | WO2003090778A3 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/22/2004 | WO2003087369A3 Ribozyme capable of specifically cleaving mmp-13 |
| 01/22/2004 | WO2003082813A3 Improvements in pharmaceutical compositions |
| 01/22/2004 | WO2003076391A3 Urokinase inhibitors, production and use thereof |
| 01/22/2004 | WO2003074569A3 Bispecific antibody point mutations for enhancing rate of clearance |
| 01/22/2004 | WO2003066087A3 Kinases involved in the regulation of energy homeostasis |
| 01/22/2004 | WO2003064383A3 Phosphorus-containing compounds & uses thereof |
| 01/22/2004 | WO2003055447A3 Heterocyclic acridone inhibitors of impdh enzyme |
| 01/22/2004 | WO2003048205A3 Novel proteins with il-6 inhibiting activity |
| 01/22/2004 | WO2003045326A3 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| 01/22/2004 | WO2003037257A3 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750 |
| 01/22/2004 | WO2003026570A3 Reduced toxicity cisplatin formulations and methods for using the same |
| 01/22/2004 | WO2003025121A3 Igf-binding protein-derived peptide or small molecule |
| 01/22/2004 | WO2003024395A8 Linked biaryl compounds |
| 01/22/2004 | WO2003022805A3 Heterocycle substituted purines as antiproliferative agents |
| 01/22/2004 | WO2003020889A3 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 01/22/2004 | WO2003008595A3 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 01/22/2004 | WO2002092573A3 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| 01/22/2004 | WO2002076439A3 Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
| 01/22/2004 | WO2002076389A3 Compositions and methods to prevent metastasis from primary malignancies |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | WO2002065986A3 Transporters comprising spaced arginine moieties |
| 01/22/2004 | US20040016013 Achieves widespread distribution, systemic expression and sustained delivery in the animal; oral gene therapy |
| 01/22/2004 | US20040016006 Chromosome 3p21.3 genes are tumor suppressors |
| 01/22/2004 | US20040015075 Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures |
| 01/22/2004 | US20040014987 Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases |
| 01/22/2004 | US20040014982 For use as fungicides or cytostatic agents |
| 01/22/2004 | US20040014979 For use as antitumor agents |
| 01/22/2004 | US20040014978 Such as (4S,7R,8S,9S,13(Z),16S(Z))-4,8-Dihydroxy-16-(1-fluoro-2-(2-methyl-4 -thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6 -dione |
| 01/22/2004 | US20040014973 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines |
| 01/22/2004 | US20040014969 Such as methyl-4'-(4-((8-(acetylamino)ethyl)-2-naphthyl)oxy) butoxy)-(1,1'-biphenyl)-4-carboxylate; for treating/ preventing melatoninergic disorders |
| 01/22/2004 | US20040014956 For increasing nuclease resistance of antisense sequences |
| 01/22/2004 | US20040014816 Novel aliphatic compounds, process for their preparation and their usage |
| 01/22/2004 | US20040014809 Novel n-( 2-phenyl-3-aminopropyl)naphtamides |
| 01/22/2004 | US20040014802 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof |
| 01/22/2004 | US20040014798 Skin disorders; hormone replacement therapy |
| 01/22/2004 | US20040014788 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht receptor agonists |
| 01/22/2004 | US20040014787 Hormone inhibitors; controlling fertility |
| 01/22/2004 | US20040014779 Testing for immunology response moderators; viricides, antitumor agents |
| 01/22/2004 | US20040014778 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 01/22/2004 | US20040014776 Anticancer agents; cyclin-dependent kinase inhibitor |
| 01/22/2004 | US20040014765 Chk-1 inhibitors |
| 01/22/2004 | US20040014759 6,5-Fused bicyclic heterocycles |
| 01/22/2004 | US20040014755 Rho-kinase inhibitors |
| 01/22/2004 | US20040014754 Urea substituted imidazoquinolines |
| 01/22/2004 | US20040014751 Antidiabetic agents |
| 01/22/2004 | US20040014743 Mbreast and prostate anticancer agents; viricides; alopecia |
| 01/22/2004 | US20040014737 Porphyron based neuton capture agents for cancer therapy |
| 01/22/2004 | US20040014723 Calcilytic compounds |
| 01/22/2004 | US20040014721 Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 01/22/2004 | US20040014708 Composition comprising immunogenic microparticles |
| 01/22/2004 | US20040014704 Reducing immunology response; sustained release |
| 01/22/2004 | US20040014698 Oral administration of therapeutic agent coupled to transporting agent |
| 01/22/2004 | US20040014694 Therapy for breast cancer |
| 01/22/2004 | US20040014693 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 01/22/2004 | US20040014684 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic |
| 01/22/2004 | US20040014672 Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/22/2004 | US20040014668 Human NK3-related prostate specific gene 1 |
| 01/22/2004 | US20040014661 Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant |
| 01/22/2004 | US20040014655 Pharmaceutical compositions containing plasma protein |
| 01/22/2004 | US20040014647 Apicidin-derivatives, their synthetic methods and anti-tumor compositions containing them |
| 01/22/2004 | US20040014635 Anticancer agents |
| 01/22/2004 | US20040014634 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals |
| 01/22/2004 | US20040014219 Comprises expression vector coding fusion protein associated cell proliferation and/or differentiation; gene therapy; animal model for disease |
| 01/22/2004 | US20040014187 Comprises genetically engineered protease for treatment tumors; gene therapy |
| 01/22/2004 | US20040014162 Regulating levels of tyrosine phosphatase activity of protein tyrosine phosphatase zeta/receptor-like protein (RPTP beta/zeta) in cells and/or tissues; antitumor agents; angiogensis inhibitors |
| 01/22/2004 | US20040014141 Comprises transcription factor referred to as dragon protein (DRG) for treating and diagnosing nervous system, skin, muscle, bone and eye disorders |
| 01/22/2004 | US20040014110 Dendritic enriched secreted lymphocyte activation molecule |
| 01/22/2004 | US20040014089 Culturing a transformant in a medium, allowing the polypeptide having phospholipase a2 activity fo form and accumulating in the culture, recovering the polypeptide thus formed |
| 01/22/2004 | US20040014057 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/22/2004 | US20040014055 Gene coding for erbin, and diagnostic and therapeutic uses thereof |
| 01/22/2004 | US20040014046 Preparing candidate vaccine agents based on a polypeptide comprising an envelope protein of a pathogenic strain of the retrovirus and selecting as the vaccine a modified polypeptide that induces an immune response |
| 01/22/2004 | US20040013748 Medication combination for hepatoma and pancreatic cancer and preparation protocol |
| 01/22/2004 | US20040013746 Antidepressants for treating manic disorders, psychosis, comprising ethyl cellulose, talc, polyvinylpyrrolidone |
| 01/22/2004 | US20040013740 Antitumor agents for treating tumor of mucosa, skin; poisons are selected from scolopenders, snakes, spiders or scorpions |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013720 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 01/22/2004 | US20040013719 Regulation of cell proliferation and differentiation using topically applied nucleric acid molecules |
| 01/22/2004 | US20040013696 Topical applying |
| 01/22/2004 | US20040013675 In situ detection of tumors; diagnosis of epilepsy, Alzheimer's disease, brain disorders |
| 01/22/2004 | US20040013660 Synergistic mixtures |
| 01/22/2004 | US20040013645 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 01/22/2004 | US20040013642 Interferon therapeutic effect-potentiating agents |
| 01/22/2004 | US20040013640 Antitumor agents; rheumatic agents; antiarthritic agents; tissue factor protein binding to antibody |
| 01/22/2004 | US20040013637 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 01/22/2004 | US20040013607 Conjugated to Y-90 through aminohexyl diethylenetriaminepentaacetic acid chelating agent |
| 01/22/2004 | DE10230631A1 Verwendungen von an Ngal bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen Uses of binding of NGAL substances for the diagnosis and treatment of cancer |
| 01/22/2004 | CA2509821A1 3-phenyl analogs of toxoflavine as kinase inhibitors |
| 01/22/2004 | CA2499465A1 Biologically active compounds |
| 01/22/2004 | CA2494245A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | CA2493675A1 Genes |
| 01/22/2004 | CA2493373A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |